Hormone-dependent prostate cancer+1
Not recruitingA Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy
A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy
- Disease:Hormone-dependent prostate cancerProstate cancer metastatic
- Substances:EnzalutamideMevrometostat
Italy- Participants:18–64 years · 65+ years
- Substances:Enzalutamide
- Sponsor:Pfizer Inc.











